COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact

Shahriar, Saimon; Rana, Sohel; Hossain, Sabbir; Karim, Ariful; Mredula, Tasneem Nayla; Nourin, Nadia; Uddin, Sahab; Amran, Shah

doi:10.2174/1381612827666210224142446

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 is caused by the SARS-CoV-2-enveloped virus [1], which became a pandemic in 2020 and is still widespread [2,3]. The COVID-19 infection has the potential to cause multi-organ, systemic complications with a greater risk of thromboembolism [4,5]. As of 2 July 2021, there were more than 182 million confirmed worldwide cases of COVID-19 reported to the WHO, with more than 3 million deaths.…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: The Oxford–AstraZeneca vaccine (Covishield) was the first to be introduced in Bangladesh to fight the ongoing global COVID-19 pandemic. As this vaccine had shown some side-effects in its clinical trial, we aimed to conduct a study assessing short-term adverse events following immunization (AEFIs) in Bangladesh. Method: A cross-sectional study was conducted on social and electronic media platforms by delivering an online questionnaire among people who had taken at least one dose of the COVID-19 vaccine. The collected data were then analysed to evaluate various parameters related to the AEFIs of the respondents. Results: A total of 626 responses were collected. Of these, 623 were selected based on complete answers and used for the analysis. Most of the respondents were between 30–60 years of age, and 40.4% were female. We found that a total of 8.5% of the total respondents had been infected with the SARS-CoV-2 virus. Our survey revealed that out of 623 volunteers, 317 reported various side-effects after taking the vaccine, which is about 50.88% of the total participants. The majority of participants (37.07%, 231/623) reported swelling and pain at the injection site and fever (25.84%, 162/623); these were some of the common localized and generalized symptoms after the COVID-19 vaccine administration. Conclusion: The side-effects reported after receiving the Oxford–AstraZeneca vaccine (Covishield) are similar to those reported in clinical trials, demonstrating that the vaccines have a safe therapeutic window. Moreover, further research is needed to determine the efficacy of existing vaccines in preventing SARS-CoV-2 infections or after-infection hospitalization.

show abstract

Section: Introductionmentioning

confidence: 99%

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…COVID-19 (coronavirus disease 2019), the etiological agent of SARS-CoV-2, is a multisystemic disease classified as a pandemic by the World Health Organization, and it poses a public health problem due to the virus's close-contact transmission and rapid spread [1]. Although mortality rates vary from country to country, mortality is known to be higher for older individuals, and a recent study reported the disease's mortality rate at 36%for patients over 64 years old [2].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 quarantine days’ effect on sarcopenic quality of life and psychological status among elderly people

Karlıbel¹,

Aksoy²,

Önen³

2023

ejhh

View full text Add to dashboard Cite

Aim: Social isolation and quarantine practices are recommended to control SARS-Cov-2. During this period, elderly individuals' physical mobility is significantly restricted, which may predispose them to sarcopenia. We aimed to investigate such pandemic restrictions' effects on elderly individuals' sarcopenic quality of life, anxiety and depression. Methods:The open-ended questionnaire study gained access to volunteers online and remotely. The 'Sarcopenic Quality of Life Scale', 'Geriatric Depression Scale-Short Form' and 'Geriatric Anxiety Scale' were used. Data were evaluated prospectively and cross-sectionally. Results:In total, 139 elderly volunteers (≥ 65age; 60% female) were included in the study. Compared to before the pandemic, respondents reports decreases in: arm strength (48.6%), leg strength (65.5%), muscle mass (55.7%), energy (67.9%), physical capacity and flexibility (64.3%), walking frequency (77.5%), walking time (79.6%), walking distance (82.4%), walking speed (88.7%) and step length (83.8%). Among coronavirus disease survivors, sarcopenic quality of life was significantly lower than those not exposed to the coronavirus disease, while depression and anxiety were higher.The 'Sarcopenic Quality of Life Scale' items 3 and 6 alone were significantly better among respondents who exercised. A negative correlation was found between sarcopenic quality of life and anxiety and depression. Conclusion:Our study showed decreased physical functions and sarcopenic quality of life among elderly individuals whose movements were restricted to their homes. This decline was more pronounced among coronavirus disease survivors and patients who had not exercised at home during this period, and it was found to be associated with anxiety and depression.

show abstract

“…The disease caused by SARS-CoV-2, called COVID-19, spread quickly. Before the end of January 2020, there were already reports of contamination in different locations around the world (RAHMAN et al, 2021;SHAHRIAR et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic efficacy of electrochemical biosensor compared to RT-PCR for diagnosis of Covid-19: a systematic review

Batista¹,

Martins²,

Espíndula³

et al. 2023

Cuad. Ed. Desar.

View full text Add to dashboard Cite

In December 2019, the new coronavirus that was named SARS-CoV-2 was identified in China. The virus spreaded quickly and in March of 2020 it was declared a pandemic by the World Health Organization. Due to the initial lack of rapid diagnoses and effective treatments, the health systems were overloaded as a consequence of the high number of infected and severe cases. The diagnostic techniques currently available have limitations, for this reason, the search for new methods with sensitive, fast, cheap and locally used techniques, such as electrochemical biosensors, has been widely explored. Given the advantages of developing electrochemical biosensors for sensitive and selective diagnosis, this systematic review aimed to search for publications on the subject and answer the following question: The diagnosis of COVID-19 performed through an electrochemical biosensor, in individuals with suspected disease is it as efficient as that performed by RT-PCR? A study protocol was developed following the PRISMA-DTA guidelines and registered with PROSPERO under the approval code CRD42021282561. Searches were carried out in six electronic databases, inclusion and exclusion criteria were applied and seventeen publications were selected for this review. Based on the data, the analyse of risk was done using QUADAS-2. The results were presented in a descriptive qualitative manner it was not possible to carry out a meta-analysis.

show abstract

COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact

Cited by 7 publications

References 0 publications

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

COVID-19 quarantine days’ effect on sarcopenic quality of life and psychological status among elderly people

Diagnostic efficacy of electrochemical biosensor compared to RT-PCR for diagnosis of Covid-19: a systematic review

Contact Info

Product

Resources

About